From Testing To Launch: A Single-Source Approach For mAbs
The rapid expansion of monoclonal antibodies (mAbs) is shifting therapeutic delivery toward highly concentrated formulations, larger injection volumes, and patient self-administration. Bringing these sensitive biologics to market requires overcoming critical development hurdles, including maintaining formulation stability, verifying drug-container compatibility, and ensuring consistent device performance across the product lifecycle. Pairing advanced containment—such as large-volume syringes and cartridges—with patient-centric delivery platforms like the Aidaptus® autoinjector and Vertiva® on-body delivery system helps address these demands early. By integrating analytical testing, engineering, and manufacturing under a coordinated, single-source strategy with Stevanato Group, biopharma teams can streamline compatibility assessments, reduce supply chain complexity, and accelerate commercialization.
Watch the full webinar to examine real-world strategies for mitigating mAb development risks and building reliable, patient-ready combination products.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Drug Delivery Leader? Subscribe today.